Sr–HT–Gahnite Spinal Cage Device
Allegra is now pleased to report the successful completion of the 8-week timeline for the large animal pilot study performed at SAHMRI (South Australian Health and Medical Research Institute).
The results of the study mark a pivotal milestone and a confirm a viable pathway to obtaining a 90 day FDA 510(k) clearance in the near future.
Read the ASX Announcement in full
Allegra confirms route to FDA approval following successful pilot animal study Sr–HT–Gahnite Spinal Cage Device